{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:10:39Z","timestamp":1769728239962,"version":"3.49.0"},"reference-count":32,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Hebei Natural Science Foundation","doi-asserted-by":"crossref","award":["H2025423167"],"award-info":[{"award-number":["H2025423167"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation Youth Fund of China","award":["81500317"],"award-info":[{"award-number":["81500317"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: This study aims to examine the roles and mechanisms of action of bellidifolin (BEL) in alleviating doxorubicin-mediated cardiotoxicity using network pharmacology and experimental validation . Materials and Methods: Mice with doxorubicin-induced cardiotoxicity were randomly assigned to control, model, BEL, and dexrazoxane (DEX) groups. Echocardiography, histological staining, network pharmacology, and molecular validation were employed to assess cardiac function and myocardial injury. Immunohistochemical staining, western blotting, and RT-qPCR were used to confirm predicted targets and fibrosis biomarkers. Results: In vivo experiments demonstrated that BEL significantly improved cardiac function, as indicated by enhanced Ejection Fraction (EF) and Fractional Shortening (FS) compared to the model group (p &lt; 0.01). BEL also notably reduced myocardial injury markers, including creatine kinase MB isoenzyme (CK-MB) and lactate dehydrogenase (LDH) (p &lt; 0.01), and alleviated doxorubicin-induced myocardial fibrosis. Network pharmacology identified 61 common target genes for BEL and cardiotoxicity. Proteinprotein interaction (PPI) network analysis highlighted 16 core genes, including transforming growth factor (TGF)-\u03b21. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses revealed that BEL\u2019s action pathways were primarily linked to the PI3K-AKT signaling pathway. Molecular docking and dynamic simulations showed a strong binding affinity between BEL and the core target TGF-\u03b21. In vivo validation confirmed that BEL significantly downregulated the expression of TGF-\u03b21, \u03b1-smooth muscle actin (SMA), collagen I (Col I), and collagen III (Col III) in myocardial tissue (p &lt; 0.01 or p &lt; 0.05), while activating the PI3K-AKT signaling pathway (p &lt; 0.01 or p &lt; 0.05). Conclusion: BEL presents as a promising therapeutic candidate for cardiotoxicity, likely through its anti-fibrotic effects via the reduction of TGF-\u03b21, \u03b1-SMA, Col I, and Col III expression, alongside regulation in the PI3K-AKT signaling pathway.<\/jats:p>","DOI":"10.31083\/fbl47028","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:05:26Z","timestamp":1769688326000},"source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of Bellidifolin in Treating Doxorubicin-Induced Cardiotoxicity: Network Pharmacology, Molecular Docking, and Experimental Verification"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9211-4006","authenticated-orcid":true,"given":"Xinmeng","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"},{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7313-8828","authenticated-orcid":true,"given":"Zhenyang","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"},{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8707-0436","authenticated-orcid":true,"given":"Fan","family":"Gao","sequence":"additional","affiliation":[{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3366-8516","authenticated-orcid":true,"given":"Jiangli","family":"Wu","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-3492","authenticated-orcid":true,"given":"Cheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"},{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2033-9487","authenticated-orcid":true,"given":"Yalei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-3511","authenticated-orcid":true,"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"},{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7779-1814","authenticated-orcid":true,"given":"Aiying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Pharmacy, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China"},{"name":"Hebei Key Laboratory of Chinese Medicine Research on Cardio-cerebrovascular Disease, 050091 Shijiazhuang, Hebei, China"},{"name":"Hebei Higher Education Institute Applied Technology Research Center on TCM Development and Industrialization, 050091 Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Li X. Doxorubicin-mediated cardiac dysfunction: Revisiting molecular interactions, pharmacological compounds and (nano)theranostic platforms. Environmental Research. 2023; 234: 116504.","DOI":"10.1016\/j.envres.2023.116504"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biology. 2020; 29: 101394.","DOI":"10.1016\/j.redox.2019.101394"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Jones IC, Dass CR. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. The Journal of Pharmacy and Pharmacology. 2022; 74: 1677\u20131688.","DOI":"10.1093\/jpp\/rgac063"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Pawar HD, Dusane S, Sharma T, Nakhate KT, Goyal SN. Doxorubicin-Induced Cardiotoxicity: Exploration of Molecular Pathogenesis and Phytocompound-Based Therapeutic Strategies. Current Pharmaceutical Design. 2025.  (Online ahead of print)","DOI":"10.2174\/0113816128410093251006160508"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. The Cochrane Database of Systematic Reviews. 2022; 9: CD014638.","DOI":"10.1002\/14651858.CD014638.pub2"},{"key":"ref6","unstructured":"Goey AKL, Schellens JHM, Beijnen JH, Huitema ADR. Dexrazoxane in anthracycline induced cardiotoxicity and extravasation. Nederlands Tijdschrift Voor Geneeskunde. 2010; 154: A1155."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zhou D, Liu W, Zhang J, Dong Y, Wu J, Zhang Y, et al. Bellidifolin ameliorates isoprenaline-induced cardiac hypertrophy by the Nox4\/ROS signalling pathway through inhibiting BRD4. Cell Death Discovery. 2023; 9: 279.","DOI":"10.1038\/s41420-023-01563-2"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Ge H, Du Z, Liu W, Wang L, Li J, Yang G, et al. Gen-miR-5 derived from Gentianella acuta inhibits PFKP to prevent fibroblast activation and alleviate myocardial fibrosis. Frontiers in Pharmacology. 2025; 16: 1578877.","DOI":"10.3389\/fphar.2025.1578877"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wei Y, Wang Y, Jiang X, Sun Y, Wang M, Wang Z, et al. Xanthones explore the mechanism of p53\/p21 signaling pathway to prevent cardiac aging and epigenetic regulation of Nrf2 gene. Archives of Gerontology and Geriatrics. 2025; 236: 116878.","DOI":"10.1016\/j.archger.2025.105759"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dai C, Sun J, Yang G, Zhang C, Zhang Y, Song Q, et al. The total xanthones from Gentianella acuta alleviate acute myocardial infarction by targeting BRD4-mediated cardiomyocyte pyroptosis and inflammation. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 2025; 147: 157156.","DOI":"10.1016\/j.phymed.2025.157156"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Zhou WW, Dai C, Liu WZ, Zhang C, Zhang Y, Yang GS, et al. Gentianella acuta improves TAC-induced cardiac remodelling by regulating the Notch and PI3K\/Akt\/FOXO1\/3 pathways. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2022; 154: 113564.","DOI":"10.1016\/j.biopha.2022.113564"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Si M, Wu M, Huo Y, Li A, Guan S, Ma D, et al. Gentianella acuta mitigates cardiovascular damage and inflammation in diet-induced hypercholesterolaemic rats. Experimental and Therapeutic Medicine. 2021; 22: 1259.","DOI":"10.3892\/etm.2021.10694"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gao F, Chen Z, Zhou L, Xiao X, Wang L, Liu X, et al. Preparation, characterization and in vitro study of bellidifolin nano-micelles. RSC Advances. 2022; 12: 21982\u201321989.","DOI":"10.1039\/d2ra02779h"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Yao TT, Yang HX, Sun JH, Zhang Y, Zhang Y, Song QH, et al. Bellidifolin Inhibits SRY-Related High Mobility Group-Box Gene 9 to Block TGF-\u03b2 Signalling Activation to Ameliorate Myocardial Fibrosis. Evidence-based Complementary and Alternative Medicine: ECAM. 2022; 2022: 6841276.","DOI":"10.1155\/2022\/6841276"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Yang HX, Sun JH, Yao TT, Li Y, Xu GR, Zhang C, et al. Bellidifolin Ameliorates Isoprenaline-Induced Myocardial Fibrosis by Regulating TGF-\u03b21\/Smads and p38 Signaling and Preventing NR4A1 Cytoplasmic Localization. Frontiers in Pharmacology. 2021; 12: 644886.","DOI":"10.3389\/fphar.2021.644886"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zhao L, Zhang H, Li N, Chen J, Xu H, Wang Y, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. Journal of Ethnopharmacology. 2023; 309: 116306.","DOI":"10.1016\/j.jep.2023.116306"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Dos Santos Nascimento IJ, de Moura RO. Molecular Dynamics Simulations in Drug Discovery. Mini Reviews in Medicinal Chemistry. 2024; 24: 1061\u20131062.","DOI":"10.2174\/138955752411240402134719"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ma YL, Huo XW, Wong C, Zhou FJ, Li SZ, Zhang H, et al. Salvianolic acid A targets glutamic-oxaloacetic transaminase 2 to ameliorate doxorubicin-induced myocardial oxidative injury by activating malate-aspartate NADH shuttle. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 2025; 148: 157492.","DOI":"10.1016\/j.phymed.2025.157492"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Curran CF, Narang PK, Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treatment Reviews. 1991; 18: 241\u2013252.","DOI":"10.1016\/0305-7372(91)90015-r"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Xu A, Deng F, Chen Y, Kong Y, Pan L, Liao Q, et al. NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2020; 130: 110525.","DOI":"10.1016\/j.biopha.2020.110525"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews. Cardiology. 2020; 17: 474\u2013502.","DOI":"10.1038\/s41569-020-0348-1"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, et al. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. Cardiovascular Toxicology. 2022; 22: 292\u2013310.","DOI":"10.1007\/s12012-022-09721-1"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhu Y, Zhang Q, Wang Y, Liu W, Zeng S, Yuan Q, et al. Identification of Necroptosis and Immune Infiltration in Heart Failure Through Bioinformatics Analysis. Journal of Inflammation Research. 2025; 18: 2465\u20132481.","DOI":"10.2147\/JIR.S502203"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Huyan Y, Chen X, Chang Y, Hua X, Fan X, Shan D, et al. Single-Cell Transcriptomic Analysis Reveals Myocardial Fibrosis Mechanism of Doxorubicin-Induced Cardiotoxicity. International Heart Journal. 2024; 65: 487\u2013497.","DOI":"10.1536\/ihj.23-302"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology. 2011; 51: 600\u2013606.","DOI":"10.1016\/j.yjmcc.2010.10.033"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods in Molecular Medicine. 2005; 117: 69\u201380.","DOI":"10.1385\/1-59259-940-0:069"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Li WQ, Tan SL, Li XH, Sun TL, Li D, Du J, et al. Calcitonin gene-related peptide inhibits the cardiac fibroblasts senescence in cardiac fibrosis via up-regulating klotho expression. European Journal of Pharmacology. 2019; 843: 96\u2013103.","DOI":"10.1016\/j.ejphar.2018.10.023"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2004; 18: 816\u2013827.","DOI":"10.1096\/fj.03-1273rev"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Fu S, Song X, Hu Y, Zhu Q, Lv X, Tang X, et al. Neotuberostemonine and tuberostemonine ameliorate pulmonary fibrosis through suppressing TGF-\u03b2 and SDF-1 secreted by macrophages and fibroblasts via the PI3K-dependent AKT and ERK pathways. Chinese Journal of Natural Medicines. 2023; 21: 527\u2013539.","DOI":"10.1016\/S1875-5364(23)60444-3"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL, et al. Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences. 2022; 23: 10146.","DOI":"10.3390\/ijms231710146"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Wang D, Jin Y, Yang M, Xue Y, Zhang X, Guo Y, et al. Cardioprotective effect of Saussurea involucrata injection against Doxorubicin-induced cardiotoxicity by network pharmacology analysis and experimental verification. Acta Biochimica et Biophysica Sinica. 2024; 57: 554\u2013568.","DOI":"10.3724\/abbs.2024170"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Qin W, Cao L, Massey IY. Role of PI3K\/Akt signaling pathway in cardiac fibrosis. Molecular and Cellular Biochemistry. 2021; 476: 4045\u20134059.","DOI":"10.1007\/s11010-021-04219-w"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/1\/10.31083\/FBL47028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:05:57Z","timestamp":1769688357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/1\/10.31083\/FBL47028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)00072-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl47028","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"47028"}}